Amifostine in combination with erythropoietin and G-CSF promotes multilineage hematopoiesis in patients with myelodysplastic syndrome

Leukemia and Lymphoma

Volumn 40, Issue 3-4, 2001, Pages 345-349

  Neumeister, P ^a   Jaeger, G ^a   Eibl, M ^a   Sormann, S ^a   Zinke, W ^a   Linkesch, W ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

Amifostine; Growth factor; MDS; Response; Therapy

Indexed keywords

AMIFOSTINE; AMINOTHIOL; DEXAMETHASONE; ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR; GROWTH FACTOR; ONDANSETRON;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL OBSERVATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOPENIA; DEEP VEIN THROMBOSIS; DOSE RESPONSE; DRUG INTERACTION; ERYTHROCYTE COUNT; HEMATOPOIESIS; HUMAN; HYPOTENSION; IN VITRO STUDY; IN VIVO STUDY; INDEPENDENCE; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT OUTCOME;

EID: 0035033017     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428190109057933     Document Type: Article

References (7)

1. Myelodysplastic syndromes: Clinical features
2. Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: Evidence for in vivo synergy
3. Use of amifostine in hematologic malignancies, myelodysplastic syndrome, and acute leukemia
4. Stimulation of hematopoiesis by amifostine in patients with myelodysplastic syndrome
5. Poor response rate to a continuous schedule of Amifostine therapy for "low/intermediate risk" patients
6. Clinical use of hematopoietic growth factors in the myelodysplastic syndromes
7. Treatment of myelodysplastic syndromes with hemopoietic growth factors